オクヤマ リョウ
OKUYAMA Ryo
奥山 亮 所属 立命館アジア太平洋大学 国際経営学部 職種 教授 |
|
言語種別 | 英語 |
発行・発表の年月 | 2023/06 |
形態種別 | 学術論文 |
査読 | 査読あり |
標題 | Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and Origin. |
執筆形態 | 単著 |
掲載誌名 | Pharmaceutics |
掲載区分 | 国外 |
出版社・発行元 | MDPI |
巻・号・頁 | 15(7),pp.1794 |
総ページ数 | 11 |
担当区分 | 筆頭著者,責任著者 |
著者・共著者 | Ryo Okuyama |
概要 | Technological trends and origin of FIC drugs approved by FDA from 2011-2022 were analyzed. The analysis reveals that the target family of FIC drugs has shifted to molecules previously considered challenging as drug targets. It also reveals that the drug modalities used for new drugs have been diversified in recent years. Over half of FIC drugs were created by small and medium enterprises (SMEs), especially young companies established in the 1990s and 2000s. All SMEs with high productivity have the strong technological capability in a specific modality. Investment in modality technologies and facilitating mechanisms to translate academic modality technologies to start-ups might be important for enhancing FIC drug development. |